FELDAN ANNOUNCES APPOINTMENT OF ELISABETH SANDOVAL LITTLE, NATHALIE CHAURET AND ANGIE JIWON CHUN TO BOARD OF DIRECTORS

Québec City, Canada, February 8, 2024 — Feldan Therapeutics (“Feldan” or the “Company”), a biopharmaceutical company specializing in the development of treatments based on the intracellular delivery of therapeutics, announces the appointment of three distinguished professionals to its board of directors: Nathalie Chauret, Elisabeth Sandoval-Little and Angie Jiwon Chun.

These changes follow Feldan’s Series B financing round and support the Company’s advancement to clinical stage, as its lead compound (FLD-103), an intralesional treatment for basal cell carcinoma, enters phase I/II later this year. At this pivotal and exciting moment in its journey, Feldan emphasizes the importance of broadening the expertise of its board with additional directors who bring a strong strategic outlook and a diverse set of skills that range from drug discovery to commercialization.

“Our team is delighted to welcome Elisabeth, Nathalie and Angie to the board of directors,” said François-Thomas Michaud, Ph.D., co-founder and Chief Executive Officer of Feldan. “Highly collaborative, insightful and skilled, they are perfectly aligned with our vision and values, and will help maintain our commitment to innovation, patient-focused solutions and continued growth opportunities. I am confident that their contributions will be significant in leading Feldan to future success.”

Elisabeth Sandoval Little currently serves as a consultant to the pharmaceutical industry and is a member of the board of directors of Procept BioRobotics and Vyne Therapeutics, Inc. Ms. Sandoval was previously a member of the board of directors of Satsuma Pharmaceuticals Inc., until its acquisition by Shin Nippon Biomedical Laboratories in June 2023, and Intersect ENT, Inc., until its acquisition by Medtronic plc in May 2022. Ms. Sandoval previously served as Chief Commercial Officer and Executive Vice-President of Corporate Strategy at Alder Biopharmaceuticals. Prior to that, she was Chief Commercial Officer for Kythera Biopharmaceuticals and spent more than 20 years at Allergan in a variety of commercial leadership roles of increasing responsibility in neurology, dermatology and aesthetics. Ms. Sandoval holds a B.S. in Biology from the University of California at Irvine and an M.B.A. from Pepperdine University.

Nathalie Chauret is Vice-President, Early Phase Development, at Bellus Health Inc., where she directs the preclinical toxicology and clinical pharmacology programs of new products. Ms. Chauret has more than 30 years of experience in the biopharmaceutical industry and a profound understanding of the drug development process. Prior to joining Bellus Health, Ms. Chauret led DMPK, pharmaceutical sciences and phase 1 clinical activities with increasing responsibilities at Merck Frosst, Virochem Pharma and Vertex Pharmaceuticals. Throughout her career, she has been involved in the discovery and development of several marketed drugs in different therapeutic areas (asthma, pain, osteoporosis and cystic fibrosis).

Angie Jiwon Chun has an impressive 18-year tenure in the pharmaceutical industry. She has served in various capacities, from research to commercial roles with a career trajectory that showcases her versatility and strategic leadership. She currently is Chief Business & Marketing Officer (CBMO) at GC CELL. Before that, she held the positions of Oncology BD & Licensing Lead at LG Chem Life Sciences, and Integrated Marketing Lead at Samsung Biologics. Her background in business development and marketing has been instrumental in forging key partnerships and driving successful mergers and acquisitions. Her journey began in research, providing her with a profound understanding of the drug development process, which laid a solid foundation for her subsequent roles. Transitioning into business-focused positions, Ms. Jiwon Chun demonstrated her adaptability and strategic vision, leading to significant growth and profitability for organizations.

Feldan’s Board of Directors includes:
- David J. Mazzo, Chairman of the Board – President and Chief Executive Officer, Lisata Therapeutics 
- Angie Jiwon Chun – Chief Business & Marketing Officer of the Global BD & Marketing Division at GC Cell
- Nathalie Chauret – Vice-President of Early Phase Development at Bellus Health Inc.
- Paul Truex – Chairman of the Board and Chief Executive Officer, Thryv Therapeutics 
- Robert J. Wills – Chairman, CymaBay Therapeutics
- Iain D. Dukes – Venture Partner, OrbiMed Advisors
- Elisabeth Sandoval Little – Consultant to the pharmaceutical industry
- François-Thomas Michaud – Co-founder and Chief Executive Officer, Feldan
- Gladys Nunez Reyes (Observer) – Director at Amgen Ventures
- Louis-Étienne Fortier (Observer) – Senior Director Life Sciences Investment Division at Investissement Québec

About Feldan:
Located in Québec City, Canada, Feldan is a biopharmaceutical company pioneering the development of treatments based on the intracellular delivery of therapeutics. Feldan has designed the Feldan Shuttle, a proprietary, peptide-based technology that enables safe and efficient delivery of various compounds inside cells. This technology unlocks the development of a new generation of therapies by giving access to intracellular targets beyond the reach of existing drugs. Feldan’s pipeline currently focuses on diseases affecting the skin and lungs.

Feldan’s operational and strategic focus is on the completion of clinical phase I/II trials of intralesional FLD-103 to treat basal cell carcinomas (BCC). BCC, the most common skin cancer and most frequent form of all cancers, affects 3.6 million people in the US and Canada each year and results in the development of tumors mainly in sun-exposed skin areas such as the face, neck and scalp. Patients affected by BCC mostly rely on surgery for removal of these tumors, an effective yet invasive and disfiguring procedure leaving patients to deal with scarring and, in some instances, a long recovery time. Feldan is also working on advancing its pulmonary delivery program towards clinical development and further leveraging its intracellular delivery technology to offer life-changing therapeutics to patients.

For more information: www.feldan.com